A key question for ESO-T01 and other in vivo candidates will be the durability of their cancer eradication. While the ...
Data are beginning to provide a clearer picture of chimeric antigen receptor T-cell therapy’s benefits and risks in lupus, ...
On 25 March, detailed Phase I trial data was published for ESO-T01, AstraZeneca’s in vivo CAR-T therapy, in patients with ...
Bridging therapy was administered to 90% of apheresed patients, with chemotherapy ± radiotherapy used in 53% and targeted ...
Day-28 complete response occurred in 54/78 B-ALL patients, with MRD negativity in 83.3% of responders and median OS 13.6 ...
Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has ...
A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...
India Today on MSN
CAR-T therapy, used for cancer, shows promise in treating lupus
For patients who have spent years managing unpredictable and debilitating autoimmune conditions like lupus, the findings ...
Researchers have discovered how mitochondrial stress drives T cell exhaustion and a potential way to restore their ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results